- Home
- NKTR vs NLSP Comparison
NKTR vs NLSP Comparison
Compare NKTR & NLSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NKTR
- NLSP
- Stock Information
- Founded
- NKTR 1990
- NLSP 2015
- Country
- NKTR United States
- NLSP Switzerland
- Employees
- NKTR 61
- NLSP N/A
- Industry
- NKTR Biotechnology: Pharmaceutical Preparations
- NLSP Biotechnology: Pharmaceutical Preparations
- Sector
- NKTR Health Care
- NLSP Health Care
- Exchange
- NKTR Nasdaq
- NLSP Nasdaq
- Market Cap
- NKTR 948.8M
- NLSP 12.4M
- IPO Year
- NKTR 1994
- NLSP 2021
- Fundamental
- Price
- NKTR $51.07
- NLSP $2.03
- Analyst Decision
- NKTR Strong Buy
- NLSP
- Analyst Count
- NKTR 6
- NLSP 0
- Target Price
- NKTR $81.67
- NLSP N/A
- AVG Volume (30 Days)
- NKTR 1.2M
- NLSP 193.3K
- Earning Date
- NKTR 11-06-2025
- NLSP 10-17-2025
- Dividend Yield
- NKTR N/A
- NLSP N/A
- EPS Growth
- NKTR N/A
- NLSP N/A
- EPS
- NKTR N/A
- NLSP N/A
- Revenue
- NKTR $74,934,000.00
- NLSP N/A
- Revenue This Year
- NKTR N/A
- NLSP N/A
- Revenue Next Year
- NKTR N/A
- NLSP N/A
- P/E Ratio
- NKTR N/A
- NLSP N/A
- Revenue Growth
- NKTR N/A
- NLSP N/A
- 52 Week Low
- NKTR $6.48
- NLSP $1.30
- 52 Week High
- NKTR $52.75
- NLSP $6.97
- Technical
- Relative Strength Index (RSI)
- NKTR 85.95
- NLSP 43.44
- Support Level
- NKTR $42.12
- NLSP $1.88
- Resistance Level
- NKTR $50.53
- NLSP $2.29
- Average True Range (ATR)
- NKTR 3.47
- NLSP 0.12
- MACD
- NKTR 1.32
- NLSP -0.01
- Stochastic Oscillator
- NKTR 93.25
- NLSP 36.59
About NKTR Nektar Therapeutics
Nektar Therapeutics is a clinical-stage, research-based drug discovery biopharmaceutical company focused on discovering and developing medicines in the field of immunotherapy. The company is focused on discovering and developing medicines in the field of immunotherapy. Its pipeline products are REZPEG (NKTR-358), REZPEG (NKTR-358), REZPEG (NKTR-358), NKTR-422, NKTR-0165, NKTR-255, and Others.
About NLSP NLS Pharmaceutics Ltd.
NLS Pharmaceutics Ltd a clinical-stage biopharmaceutical company focused on the discovery and development of inventive therapies for patients with rare and complex CNS disorders with unmet medical needs. Its compound, mazindol, a triple monoamine reuptake inhibitor and partial orexin receptor 2 agonist, in a proprietary ER formulation, is being developed for the treatment of narcolepsy, IH (follow-on indication), and potentially ADHD (back-up indication). Its lead products are Quilience, to treat narcolepsy and Nolazol, to treat ADHD.